ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY Patent applications |
Patent application number | Title | Published |
20160032383 | PANEL OF microRNA BIOMARKERS IN HEALTHY AGING - Methods are provided for determining if a subject is likely to develop an age-related disease based on miRNA signatures. Related methods of treatment are also provided. | 02-04-2016 |
20160002337 | HHLA2 AS A NOVEL INHIBITOR OF HUMAN IMMUNE SYSTEM AND USES THEREOF - Provided are methods of treating an autoimmune disease in a subject, or of suppressing transplant rejection in a subject, or of treating a cancer in a subject, as well as compositions therefor. | 01-07-2016 |
20150368316 | A SELECTIVE HIGH-AFFINITY IMMUNE STIMULATORY REAGENT AND USES THEREOF - Isolated polypeptides comprising a mutant programmed cell death 1 (PD-1) polypeptide and fusion polypeptides comprising an isolated mutant PD-1 polypeptide fused to an immunoglobulin domain polypeptide are provided. Further provided are methods of using a composition comprising the fusion polypeptide for stimulating T cell activation for treating disorders including a tumor or an infection. | 12-24-2015 |
20150366942 | GENE TRANSFER FOR REGULATING SMOOTH MUSCLE TONE - The invention provides methods of regulating smooth muscle tone in a subject, comprising the introduction, into smooth muscle cells of the subject, of a DNA sequence encoding a potassium channel protein involved in the regulation of smooth muscle tone, and expression of the DNA sequence in a sufficient number of smooth muscle cells of the subject to regulate smooth muscle tone in the subject. The invention provides methods of gene transfer for treating erectile dysfunction, bladder dysfunction, and other smooth muscle disorders. | 12-24-2015 |
20150359815 | PAK1 INHIBITION FOR TREATMENT OF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES - Methods are disclosed for treating acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) using inhibition of p21 protein (Cdc42/Rac)-activated kinase (PAK1). | 12-17-2015 |
20150335671 | SMALL-MOLECULE BINDING SITE ON PRO-APOPTOTIC BAX REGULATES INHIBITION OF BAX ACTIVITY - Methods are provided for identifying an agent as a selective inhibitor of a Bcl-2-associated x-protein (BAX). | 11-26-2015 |
20150329643 | IDENTIFICATION AND USE OF NEW TUMOR-PROMOTING GENE IN HEMATOLOGICAL MALIGNANCIES - Methods are provided for diagnosing and treating a blood cancer or a myelodysplastic syndrome in a subject. Associated compositions and kits therefor are also provided. | 11-19-2015 |
20150313935 | ENHANCED NITRIC OXIDE DELIVERY AND USES THEREOF - Methods and compositions are disclosed that enhance delivery of nitric oxide (NO) by combining nitric oxide releasing nanoparticles (NO-np) with exogenous glutathione (GSH), as well as therapeutic uses of the methods and compositions. | 11-05-2015 |
20150306177 | THERAPY FOR RADIATION-INDUCED LUNG INJURY - Methods are disclosed for therapy of radiation-induced lung injury and other lung diseases using R-spondin | 10-29-2015 |
20150299336 | THERAPEUTIC AND DIAGNOSTIC TARGET GENE IN ACUTE MYELOID LEUKEMIA - Methods are provided for treating a cancer in a subject comprising administering to the subject an agent which inhibits expression of an HLX gene in the subject, or an agent which inhibits activity of an expression product of the HLX gene, and also for diagnosing a subject as likely to develop a cancer comprising determining whether a stem cell obtained from the subject expresses a HLX gene at a level in excess of predetermined control level. Kits therefor are also provided. | 10-22-2015 |
20150290250 | REGENERATION OF CORONARY ARTERY BY CORONARY ENDOTHELIAL SPECIFIC PROGENITOR CELLS - Methods and products are provided for producing an artery-specific endothelial cell. Also provided are methods for treating a tumor in a subject. | 10-15-2015 |
20150260714 | SEROLOGIC TEST FOR THE RAPID DIAGNOSIS OF ACTIVE TUBERCULOSIS - The present invention relates to methods and kits for detecting active tuberculosis infection in a subject using serological techniques and a first agent capable of binding an IgG, IgA and/or IgM directed to the first protein present in or on a | 09-17-2015 |
20150238532 | METHODS TO ISOLATE HUMAN MESENCHYMAL STEM CELLS - A method of obtaining a population of PDGFRα | 08-27-2015 |
20150231165 | TREATMENT AND PREVENTION OF P. AERUGINOSA INFECTIONS USING COFORMYCIN ANALOGS - Methods and devices are disclosed for treating or preventing infections in a subject due to | 08-20-2015 |
20150224188 | USE OF MEMBRANE VESICLE-BASED VACCINE AGAINST M. TUBERCULOSIS - Provided are compositions comprising a plurality of isolated | 08-13-2015 |
20150191730 | APTAMER-TARGETTED ANTIGEN DELIVERY - A composition is provided comprising an oligonucleotide aptamer conjugated to an antigen, wherein the aptamer is directed against a cell-surface target of an antigen-presenting cell. Also provided are methods of delivering an antigen to a dendritic cell and of eliciting an immune response in a subject. | 07-09-2015 |
20150190419 | METHOD TO TREAT OR PREVENT HERPESVIRUS INFECTIONS - Methods and compositions are provided for inhibiting or treating a herpesvirus infection in a subject using inhibitors of mammalian Akt. | 07-09-2015 |
20150147271 | TARGETS FOR DIAGNOSIS, PROGNOSIS AND THERAPY OF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES - Methods are disclosed for diagnosis, prognosis and therapy of acute myeloid leukemia and myelodysplastic syndromes using interleukin 1 receptor accessory protein and other targets. | 05-28-2015 |
20150140038 | MYCOBACTERIUM TUBERCULOSIS DeltaESX-3 MUTANTS - Isolated mutant | 05-21-2015 |
20150125516 | TRANSFERRIN RECEPTOR APTAMERS AND APTAMER-TARGETED DELIVERY - Aptamers targeted to a human transferrin receptor which do not compete with transferrin for binding are provided. Compositions and methods for aptamer-targeted liposomal drug delivery are also provided. | 05-07-2015 |
20150105447 | FIDGETIN-LIKE 2 AS A TARGET TO ENHANCE WOUND HEALING - Methods of treating a wound in a subject are provided comprising administering to the subject an amount of an inhibitor of Fidgetin-like 2. Compositions and pharmaceutical compositions comprising an amount of an inhibitor of Fidgetin-like 2 are also provided. Methods are also provided for identifying an inhibitor of Fidgetin-like 2. | 04-16-2015 |
20150104442 | PHOSPHOCOFILIN: COFILIN CO-LOCALIZATION INTENSITY AS A PREDICTOR OF METASTATIC RECURRENCE - Methods and products are provided for determining if a subject having a tumor is at risk of metastasis of the tumor. Specifically, the methods comprise detecting phosphorylated cofilin, and both phosphorylated and non-phosphorylated cofilin; quantifying the phosphorylated cofilin, and the total of phosphorylated and nonphosphorylated cofilin; and determining if a subject having the tumor is likely to experience metastasis of the tumor, based on the ratio of the amount of detected phosphorylated cofilin: total amount of phosphorylated and non-phosphorylated cofilin detected. Further disclosed are the types of tumor metastases that can be determined using the methods provided. | 04-16-2015 |
20150057331 | NOVEL CELLULAR TARGETS FOR HIV INFECTION - Methods and compositions are provided for treating HIV infection and for inhibiting HIV infection, and for identifying purinergic receptor antagonists or Panx 1 hemi-channel blockers useful therefor. The invention provides a method of treating a mammalian subject having an HIV infection, or suspected of having been exposed to HIV, comprising administering to the mammalian subject an amount of (i) an antagonist of a Panx 1 hemichannel, or (ii) of an inhibitor of a purinergic receptor, effective to inhibit (a) HIV fusion with a target cell, or (b) HIV replication, or (c) HIV entry into a target cell, or two or more of (a), (b) and (c). | 02-26-2015 |
20150044234 | MENAINV AND CANCER INVASION AND METASTASIS - Methods and compositions are provided for diagnosing or inhibiting invasion or metastasis of a cancer in a subject based on Mena | 02-12-2015 |
20150017146 | METHOD OF ENHANCING EFFICACY OF BLOOD TRANSFUSIONS - A method of improving the efficacy of a blood transfusion into a subject is provided comprising administering a composition comprising an EAF PEGylated-blood protein into the subject, prior to, during, or subsequent to the blood transfusion. | 01-15-2015 |
20140370495 | RECOMBINANT MYCOBACTERIOPHAGES FOR DELIVERY OF NUCLEIC ACIDS OF INTEREST INTO MYCOBACTERIA - Methods are provided for detecting mycobacteria in a sample, including clinical samples. Methods are also provided for determining susceptibility of mycobacterial strains to known or potential antibiotic agents, as are kits therefor. Recombinant mycobacteriophages are also provided comprising heterologous nucleic acids of interest. | 12-18-2014 |
20140370027 | INHIBITION OF MACROPHAGE-SYNTHESIZED WNT7B TO INHIBIT TUMOR ANGIOGENESIS AND METASTASIS - The present invention provides methods of inhibiting angiogenesis in a malignant tumor, inhibiting metastasis of a malignant tumor and of inhibiting transformation of a benign tumor to a malignant tumor. The present invention also provides assays for identifying inhibitors of angiogenesis in a malignant tumor, inhibitors of metastasis of a malignant tumor and of inhibitors of transformation of a benign tumor to a malignant tumor. | 12-18-2014 |
20140363493 | LIPID NANOPARTICLES FOR TARGETED siRNA DELIVERY - The present invention addresses a need for improved vehicles for delivering small interfering RNAs (siRNAs). | 12-11-2014 |
20140363407 | NEURAL STEM CELL THERAPY FOR OBESITY AND DIABETES - Methods are provided of treating obesity or an obesity comorbidity in a mammalian subject comprising administering to the subject an amount of an agent effective to treat obesity or the obesity comorbidity, which agent inhibits (i) IκB kinase β (IKKβ) activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) or (ii) Notch signaling in a manner so as to permit the agent to enter the hypothalamus of the subject. Assays are also provided for identifying candidate agents for treating obesity. | 12-11-2014 |
20140356354 | THERAPY FOR FILOVIRUS INFECTION - The present invention addresses a need for improved treatments for filovirus infections. | 12-04-2014 |
20140329714 | STAT3 ACTIVATION AS A MARKER FOR CLASSIFICATION AND PROGNOSIS OF DLBCL PATIENTS - Methods are disclosed for determining classification and prognosis of patients with diffuse large B-cell lymphoma (DLBCL) using activation of signal transducer and activator of transcription 3 (STAT3). | 11-06-2014 |
20140329692 | METHOD FOR MEASURING DNA METHYLATION PROFILES - Methods are provided for determining epimutations in a nucleic acid sequence of a cell. | 11-06-2014 |
20140322708 | METHOD FOR MEASURING SOMATIC DNA MUTATIONAL PROFILES - Methods are provided for determining if an agent causes somatic mutations in a genome, and kits, systems and computer-readable medium therefor. | 10-30-2014 |
20140314786 | HUMAN INVASION SIGNATURE FOR PROGNOSIS OF METASTATIC RISK - Methods and products are provided for determining if a subject having a tumor is (i) at risk of metastasis of the tumor, or (ii) at risk of recurrence of the tumor after treatment of the tumor. Methods of treatment of cancer, tumors and metastasis are also provided. | 10-23-2014 |
20140308670 | SIMULTANEOUS EXTRACTION OF DNA AND RNA FROM FFPE TISSUES - The present provides methods and kits for extracting DNA and RNA from FFPE tissues and samples. | 10-16-2014 |
20140302050 | TARGETING AN AMPHIREGULIN-DERIVED CELL SURFACE NEO-EPITOPE - Antibodies to an amphiregulin neo-epitope, fragments thereof, and compositions comprising such are provided. Therapies for cancers in which cells thereof express amphiregulin are provided, as well as assays for identifying additional agents useful in such therapies. | 10-09-2014 |
20140294854 | TARGET DIRECTED TO ADIPOCYTES, METHODS AND ASSAYS FOR TREATMENT OF OBESITY - The present invention provides compositions and methods for treating obesity in a subject by administering an inhibitor of UBE2L6 or an activator of adipocyte triglyceride lipase to the subject. | 10-02-2014 |
20140256636 | PEGYLATED HEMOGLOBIN AND ALBUMIN AND USES THEREOF - The present invention provides PEGylated hemoglobins and PEGylated albumins comprising polyethylene glycol (PEG) conjugated to hemoglobin or to albumin, wherein the PEG is a maleimide PEG, an alkylamide PEG, an iodoacetamide PEG, a p-nitro thio-phenyl PEG, a vinyl sulfone PEG, or a mixed disulfide PEG; and PEGylated albumins and PEGylated hemoglobins comprising polyethylene glycol (PEG) attached to a thiolated amino group of albumin or hemoglobin, wherein the amino group is thiolated using dithio sulfo succinimidyl propionate (DTSSP) or dithiosuccinimidyl propionate (DTSP) or dithiobispropionimidate. The invention also provides methods of preparing PEGylated hemoglobins and PEGylated albumins comprising a) reacting hemoglobin or albumin with a thiolating agent and with a PEGylating agent, and b) capping unPEGylated reactive thiols of hemoglobin or albumin with N-ethyl maleimide. | 09-11-2014 |
20140255402 | METHOD OF TREATING LEUKEMIA IN A MAMMAL - The present invention provides a method of treating a leukemia in a mammal comprising sequentially administering to the mammal an amount of an immunotoxin and an amount of a chemotherapeutic agent effective to treat the leukemia. | 09-11-2014 |
20140248281 | ERYTHROPOIETIC ROLE OF RESIDENT MACROPHAGES IN HEMATOPOIETIC ORGANS - Methods of determining the erythroid prognosis of an anemia, methods of treating a blood disorder in a subject comprising an anemia, and methods of treating a blood disorder in a subject comprising an expanded erythron are all provided. | 09-04-2014 |
20140220138 | ENHANCED NITRIC OXIDE DELIVERY AND USES THEREOF - Methods and compositions are disclosed that enhance delivery of nitric oxide (NO) by combining nitric oxide releasing nanoparticles (NO-np) with exogenous glutathione (GSH), as well as therapeutic uses of the methods and compositions. | 08-07-2014 |
20140194315 | METHODS AND COMPOSITIONS FOR RAPID FUNCTIONAL ANALYSIS OF GENE VARIANTS - Methods and compositions are disclosed for rapid functional analysis of gene variants based on analysis of protein-protein and protein-nucleic acid interactions. | 07-10-2014 |
20140187604 | THERAPEUTIC AND DIAGNOSTIC TARGET GENE IN ACUTE MYELOID LEUKEMIA - Methods are provided for treating a cancer in a subject comprising administering to the subject an agent which inhibits expression of an HLX gene in the subject, or an agent which inhibits activity of an expression product of the HLX gene, and also for diagnosing a subject as likely to develop a cancer comprising determining whether a stem cell obtained from the subject expresses a HLX gene at a level in excess of predetermined control level. Kits therefor are also provided. | 07-03-2014 |
20140179610 | TREATMENT OF TYPE 2 DIABETES, METABOLIC SYNDROME, MYOCARDIAL INJURY AND NEURODEGENERATION WITH HUMANIN AND ANALOGS THEREOF - Provided are methods of using humanin and humanin analogs to treat a mammal exhibiting or at risk for insulin resistance, increase insulin sensitivity in a mammal exhibiting or at risk for insulin resistance, treat type-2 diabetes mellitus, metabolic syndrome, and neurodegeneration, treat and prevent myocardial injury, and determine longevity. | 06-26-2014 |
20140147836 | METHODS AND APPARATUS FOR IMAGING MOLECULES IN LIVING SYSTEMS - Methods and apparatus are disclosed for imaging molecular interactions in living cells at high resolution, low light levels and high acquisition speeds. | 05-29-2014 |
20140147379 | RADIOBACTERIA FOR THERAPY OF CANCER - A method of treating a tumor in a subject, or reducing or preventing metastasis of a tumor in a subject, is provided comprising administering to the subject an amount of a bacteria labelled with, or comprising, one or more radionuclides so as to treat the tumor in the subject, or so as to reduce or prevent metastasis of the tumor in the subject. Radiobacteria-containing compositions and pharmaceutical compositions are also provided. | 05-29-2014 |
20140113869 | Gbetagamma BINDING SITE ON THE PIK3CB GENE PRODUCT AND METHODS OF USE - Methods of treating a disease in a subject are provided comprising administering to the subject an amount of an agent which reduces, or prevents, interaction of a Gβγ with a pi 110β effective to treat the disease. Methods are also provided for identifying an inhibitor of interaction between a Gβγ and a ρ110β. Compositions are provided comprising a peptide comprising amino acid residues having the KAAEIASSDSANVSSRGGKKFLPV (SEQ ID NO:6). | 04-24-2014 |
20140088176 | GENE TRANSFER FOR REGULATING SMOOTH MUSCLE TONE - The invention provides methods of regulating smooth muscle tone in a subject, comprising the introduction, into smooth muscle cells of the subject, of a DNA sequence encoding a potassium channel protein involved in the regulation of smooth muscle tone, and expression of the DNA sequence in a sufficient number of smooth muscle cells of the subject to regulate smooth muscle tone in the subject. The invention provides methods of gene transfer for treating erectile dysfunction, bladder dysfunction, and other smooth muscle disorders. | 03-27-2014 |
20140066373 | TREATING DIABETES WITH OXYTOCIN OR OXYTOCIN ANALOGS - Methods are provided of treating or preventing diabetes in a subject comprising administering to the subject an amount of oxytocin or an oxytocin analog. Methods are also provided of increasing insulin secretion in a subject comprising administering to the subject an amount of oxytocin or an oxytocin analog. | 03-06-2014 |
20140066319 | ALTERNATIVELY SPLICED mRNA ISOFORMS AS PROGNOSTIC INDICATORS FOR METASTATIC CANCER - The present invention provides a method for identifying a tumor as likely to metastasize, or likely to have metastasized, comprising obtaining a sample of the tumor and quantitating alternatively spliced mRNA isoforms of a cell motility gene, a cell adhesion gene and/or an actin cytoskeletal remodeling gene in the sample, or any specified genes or the level of RNA binding proteins compared to a predetermined non-metastasizing control. | 03-06-2014 |
20140057966 | METASTASIS SPECIFIC SPLICE VARIANTS OF MENA AND USES THEREOF IN DIAGNOSIS, PROGNOSIS AND TREATMENT OF TUMORS - Methods and kits for diagnosis, prognosis and treatment of metastatic tumors are provided where the metastatic tumor is characterized by changes in expression of +++, ++ and/or 11 | 02-27-2014 |
20140051661 | NOVEL LIPOGENIC INHIBITORS AND USES THEREOF - The present invention provides resveratrol-based boron-containing analog! methods of use thereof in treatment of dyslipidemias and cancer. | 02-20-2014 |
20140044789 | MELANIN NANOSHELLS FOR PROTECTION AGAINST RADIATION AND ELECTRONIC PULSES - This invention provides melanin nanoshells and their use for protection against radiation, particularly ionizing radiation, and electronic pulses, and methods of making materials comprising melanin nanoshells. | 02-13-2014 |
20140037685 | ADJUVANTS THAT ACTIVATE ADAPTIVE IMMUNE SYSTEM BY STIMULATING NLRP3 - A method of identifying an agent, or combination of agents, as a candidate immunological adjuvant is provided comprising contacting a cell comprising a Nod-like receptor (Nlrp3) with the agent. Methods of enhancing immune responses to vaccines are also provided. | 02-06-2014 |
20140037674 | ORAL ADMINISTRATION OF MELANIN FOR PROTECTION AGAINST RADIATION - Methods and compositions are provided for alleviating and/or preventing one or more side effects associated with exposure to radiation in a subject exposed to radiation or at risk for exposure to radiation comprising oral administration to the subject of an amount of an edible source of melanin effective to alleviate a side effect associated with radiation. | 02-06-2014 |
20140037551 | ANTIBODIES TO HUMAN B7X FOR TREATMENT OF METASTATIC CANCER - Methods are provided for treating metastatic cancer in patients having metastatic cancer or for preventing metastasis in cancer patients at risk for metastasis comprising administering to the patient an antibody to B7x, or an active antibody fragment that binds B7x, in an amount effective to treat or prevent metastasis. | 02-06-2014 |
20130323279 | Human Endogenous Retrovirus Polypeptide Compositions and Methods of Use Thereof - The present invention provides isolated HERV polypeptides; and compositions, including immunogenic compositions, comprising a HERV polypeptide. The present invention provides immunogenic compositions comprising a nucleic acid comprising a nucleotide sequence encoding a HERV polypeptide. The immunogenic compositions are useful for stimulating a T cell immune response to a lentiviral peptide. The present invention further provides methods of stimulating an immune response in an individual to a retrovirus- or lentivirus-infected cell. The present invention further provides methods of treating cancers in which HERV polypeptides are expressed. Also provided are methods of treating disorders, involving decreasing an immune response to a HERV polypeptide. | 12-05-2013 |
20130280254 | MACROPHAGE-SYNTHESIZED CCL3 PROMOTES BREAST CANCER METASTASIS - Methods and compositions are provided for inhibiting metastasis of a tumor in a subject, or of inhibiting progression of a primary tumor in a subject which requires macrophages for progression. | 10-24-2013 |
20130274220 | METHODS, ASSAYS AND COMPOUNDS FOR TREATING BACTERIAL INFECTIONS BY INHIBITING METHYLTHIOINOSINE PHOSPHORYLASE - The present invention discloses methods for treating bacterial infections in a subject comprising administering to the subject a sub-growth inhibiting amount of a 5′-methylthioinosine phosphorylase (MTIP) inhibitor, as well as assays for identifying such inhibitors, and compounds and pharmaceutical compositions comprising the inhibitors. | 10-17-2013 |
20130261061 | METHOD OF ENHANCING EFFICACY OF BLOOD TRANSFUSIONS - A method of improving the efficacy of a blood transfusion into a subject is provided comprising administering a composition comprising an EAF PEGylated-blood protein into the subject, prior to, during, or subsequent to the blood transfusion. | 10-03-2013 |
20130244333 | BIOLOGICAL MARKERS FOR LONGEVITY AND DISEASES AND USES THEREOF - This invention provides methods of using of the sizes and levels of high-density lipoprotein (HDL) and low-density lipoprotein (LDL) particles, the −641 allele of the promoter of the gene encoding apolipoprotein C-3 (APOC-3), the 405 allele of the gene encoding cholesteryl ester transfer protein (CETP), and plasma levels of insulin-like growth factor-1 (IGF-1), adiponectin, CETP and APOC-3, for determining and increasing an individual's likelihood of longevity and of retaining cognitive function during aging, and for determining and decreasing an individual's likelihood of developing a cardiovascular-, metabolic- or age-related disease. | 09-19-2013 |
20130231351 | SIR2 REGULATION - Compounds are disclosed which inhibit SIR2 base exchange more than deacetylation, thus enhancing SIR2 deacetylation activity. Methods of using the compounds for enhancing SIR2 deacetylation activity and increasing longevity of an organism are also disclosed. Methods for screening for compounds that enhance SIR2 deacetylation activity and increase longevity of an organism are additionally disclosed. | 09-05-2013 |
20130225690 | VITAMIN K FOR PREVENTION AND TREATMENT OF SKIN RASH SECONDARY TO ANTI-EGFR THERAPY - The invention provides methods and compositions for treating and preventing a skin rash secondary to anti-epidermal growth factor receptor (EGFR) therapy, where the method comprises applying a vitamin K analog or a phosphatase inhibitor to the skin. | 08-29-2013 |
20130223714 | METHODS FOR QUANTITATIVE ASSESSMENT OF VOLUMETRIC IMAGE FROM A SUBJECT AND USES THEROF - Methods and systems are disclosed for assessing a quantitative image volume from an individual subject comprising comparing the image from the subject to images from a control group of subjects using voxel-wise comparison. The methods allow detection of pathologies or lesions in the individual subject being assessed. | 08-29-2013 |
20130209433 | MODULATION OF AMINO ACID METABOLISM IN THE HYPOTHALAMUS - Methods for reducing peripheral blood glucose levels, food intake, glucose production, gluconeogenesis, triglyceride levels, and low density lipoprotein (VLDL) levels in mammals are provided. Also provided are methods of increasing glucose production and food intake in mammals. Further provided are methods of treating a disorder selected from the group consisting of obesity, type 2 diabetes, type 1 diabetes, hyperglycemia, insulin resistance, glucose intolerance, leptin resistance, metabolic syndrome, heart failure, ischemia, coronary heart disease, familial lipoprotein lipase deficiency, hypopituitarism, hyperlipidemia, hypertriglyceridemia, hyper-VLDLemia, atherosclerosis, hypercholesterolemia, hypertension, and any combination of the foregoing. The methods involve manipulations of amino acid presence or metabolism in the hypothalamus of the mammal. | 08-15-2013 |
20130164325 | CERAMIDE-LIKE GLYCOLIPID-ASSOCIATED BACTERIAL VACCINES AND USES THEREOF - The invention is directed compositions and methods related to bacterial cells that are physically associated with ceramide-like glycolipids for use as antigen carriers for heterologous antigens. The invention further relates to methods of incorporating ceramide-like glycolipid to bacterial cell walls. The compositions and methods of the present invention are useful for the prevention and treatment of diseases. | 06-27-2013 |
20130150428 | MIR27B IS A NOVEL TARGET FOR TREATMENT OF LIVER FIBROSIS - Methods are provided for treating fibrosis of a tissue, including fibrosis of the liver, using combinations of antagomirs and/or locked nucleic acids. Compositions therefor are also provided. | 06-13-2013 |
20130095492 | METHOD OF DETECTING TAU PROTEIN AND TAU FRAGMENTS IN SERUM - The present invention provides quantitative methods for the detection of tau protein and/or tau fragments. More specifically, the present invention provides quantitative methods for diagnosing a tauopathy or ruling out a tauopathy as the cause of disease, particularly the diagnosis and ruling of Alzheimer's disease. The present invention further provides a method for diagnosing a tauopathy by computing the ratio of two detected tau proteins or tau fragments. | 04-18-2013 |
20130090355 | CHEMICAL AGENTS FOR THE PREVENTION OF INHIBITION OR TUMOR METASTASIS - The present invention provides methods of preventing or inhibiting tumor metastasis in a subject by administering a therapeutically effective amount of (1) a compound from a group of enumerated compounds, or a pharmaceutically acceptable salt thereof; (2) an agent that covalently modifies at least one cysteine residue of S100A4 protein; or (3) an agent that inhibits the interaction between S100A4 and myosin-IIA. | 04-11-2013 |
20130084336 | ENHANCED NITRIC OXIDE DELIVERY AND USES THEREOF - Methods and compositions are disclosed that enhance delivery of nitric oxide (NO) by combining nitric oxide releasing nanoparticles (NO-np) with exogenous glutathione (GSH), as well as therapeutic uses of the methods and compositions. | 04-04-2013 |
20130045916 | TREATMENT OF TYPE 2 DIABETES, METABOLIC SYNDROME, MYOCARDIAL INJURY AND NEURODEGENERATION WITH HUMANIN AND ANALOGS THEREOF - Provided are methods of using humanin and humanin analogs to treat a mammal exhibiting or at risk for insulin resistance, increase insulin sensitivity in a mammal exhibiting or at risk for insulin resistance, treat type-2 diabetes mellitus, metabolic syndrome, and neurodegeneration, treat and prevent myocardial injury, and determine longevity. | 02-21-2013 |
20120322797 | SELECTIVE BETA-GLUCURONIDASE INHIBITORS AS A TREATMENT FOR SIDE EFFECTS OF CAMPTOTHECIN ANTINEOPLASTIC AGENTS - Compounds, compositions and methods are provided that comprise selective β-glucuronidase inhibitors for both aerobic and anaerobic bacteria, especially enteric bacteria normally associated with the gastrointestinal tract. The compounds, compositions and methods can be for inhibiting bacterial β-glucuronidases and for improving efficacy of camptothecin-derived antineoplastic agents or glucuronidase-substrate agents or compounds by attenuating the side effects caused by reactivation by bacterial β-glucuronidases of glucuronidated metabolites of camptothecin-derived antineoplastic agents or glucuronidase-substrate agents or compounds. | 12-20-2012 |
20120269720 | DETECTION OF HEPATIC INSULIN RESISTANCE - Disclosed are methods for determining whether a subject may have hepatic insulin resistance, for diagnosing hepatic insulin resistance, and for assessing the prognosis of a subject with hepatic insulin resistance, comprising determining the level of expression of major facilitator superfamily domain 2 protein (Mfsd2) in a subject's liver, where overexpression of Mfsd2 is indicative of hepatic insulin resistance. | 10-25-2012 |
20120238577 | PROSTAGLANDIN TRANSPORTER INHIBITORS AND USES THEREOF - Disclosed are compounds for inhibiting prostaglandin transporter (PGT) activity, pharmaceuticals compositions including the compounds, and methods of treating subjects using the compounds. | 09-20-2012 |
20120213697 | VERSATILE NANOPARTICULATE BIOMATERIAL FOR CONTROLLED DELIVERY AND/OR CONTAINMENT OF THERAPEUTIC AND DIAGNOSTIC MATERIAL - The invention provides compositions for controlled delivery and/or containment of therapeutic and/or diagnostic agents comprising the agent or agents encapsulated by a matrix containing chitosan, polyethylene glycol (PEG) and/or polyvinyl alcohol (PVA), and tetra-methoxy-ortho-silicate (TMOS) or tetra-ethoxy-ortho-silicate (TEOS), as well as methods for preparing the compositions, and uses of the compositions for therapy and imaging. | 08-23-2012 |
20120189702 | CELL THERAPY FOR TREATMENT OF LIVER FAILURE - Disclosed are methods for treating liver failure in a subject comprising transplanting hepatocytes or stem or progenitor cells in an extrahepatic site in the subject in an amount sufficient to provide liver support and/or induce liver regeneration, where the transplanted hepatocytes or stem or progenitor cells are used along with extracellular matrix-coated microcarriers. | 07-26-2012 |
20120171707 | ASSAY FOR INHIBITORS OF SUMO AND SUMO-TARGETED UBIQUITIN LIGASE PATHWAY - The present invention provides a method for determining a putative agent that inhibits the SUMO or the SUMO-targeted ubiquitin ligase pathway comprising the steps of contacting mutant MOT1 cells with the putative agent under conditions (1) permitting mutant MOT1 cell growth in the presence of a SUMO or SUMO-targeted ubiquitin ligase pathway inhibitor and (2) not permitting mutant MOT1 cell growth in the absence of a SUMO or SUMO-targeted ubiquitin ligase pathway inhibitor, and measuring cell growth. | 07-05-2012 |
20120128690 | METHODS FOR DETERMINING AGENTS THAT TREAT OR PREVENT OBESITY AND/OR OBESITY RELATED DISEASES AND METHODS FOR TREATMENT THEREWITH - The present invention provides methods for determining a putative agent that treats or prevent obesity and/or obesity related diseases comprising contacting cells with the putative agent and measuring the activity and/or level of Maf1 and/or the activity and/or level of KIAA1875. The present invention also provides the agent identified by the methods herein and methods of treating or preventing obesity and/or obesity related diseases in a subject comprising administering to the subject a therapeutically effective amount of an agent that inhibits or downregulates Maf1 and/or activates or upregulates KIAA1875. | 05-24-2012 |
20120020970 | METHODS OF EVALUATING PATIENTS - Methods of treating patients and evaluating patients for disease stage and/or severity are disclosed. | 01-26-2012 |
20110178102 | SIR2 REGULATION - Compounds are disclosed which inhibit SIR2 base exchange more than deacetylation, thus enhancing SIR2 deacetylation activity. Methods of using the compounds for enhancing SIR2 deacetylation activity and increasing longevity of an organism are also disclosed. Methods for screening for compounds that enhance SIR2 deacetylation activity and increase longevity of an organism are additionally disclosed. | 07-21-2011 |
20110171223 | Anti-peptide antibodies that cross react with protective antigen of bacillus anthracis and uses thereof - The present invention provides a purified peptide comprising at least one of the sequences LKQKSSNSRKKRSTS (SEQ ID NO:1), or VKNKRTFLSPWISNI (SEQ ID NO:2) as well as a vaccine, a method to protect or treat an animal from anthrax toxin, a method of making a vaccine and the use of the peptide. The present invention also provides a monoclonal antibody that specifically binds to a peptide sequence comprising at least one of the following peptide sequences: LKQKSSNSRKKRSTS (SEQ ID NO:1), or VKNKRTFLSPWISNI (SEQ ID NO:2) as well as a method to protect or treat an animal from anthrax toxin, a method of making a vaccine, a pharmaceutical composition, a method of making a pharmaceutical composition, and the use of the monoclonal antibody. | 07-14-2011 |
20110053146 | COMPOUNDS AND METHODS FOR DETECTING RICIN AND USES THEREOF - This application provides fluorescent probes, substrates, kits and methods for detecting the presence or absence of an enzyme, such as ricin, that catalyzes the release of adenine from a GAGA RNA tetraloop. | 03-03-2011 |
20100324148 | VITAMIN K FOR PREVENTION AND TREATMENT OF SKIN RASH SECONDARY TO ANTI-EGFR THERAPY - The invention provides methods and compositions for treating and preventing a skin rash secondary to anti-epidermal growth factor receptor (EGFR) therapy, where the method comprises applying a vitamin K analog or a phosphatase inhibitor to the skin. | 12-23-2010 |
20100226919 | Antitumoral Treatments - The present invention relates to combinations of PM02734 with EGFR tyrosine kinase inhibitors, and the use of these combinations in the treatment of cancer. | 09-09-2010 |
20100183549 | BACTERIAL VACCINES WITH CELL WALL-ASSOCIATED CERAMIDE-LIKE GLYCOLIPIDS AND USES THEREOF - The invention is directed compositions and methods related to bacterial cells physically associated with ceramide-like glycolipids. The invention allows for delivery of ceramide-like glycolipid adjuvants directly to the same cells that become infected with a bacterial vaccine. The compositions and methods of the present invention are useful for the prevention and treatment of diseases. | 07-22-2010 |
20100104548 | MODULATION OF AMINO ACID METABOLISM IN THE HYPOTHALAMUS - Methods for reducing peripheral blood glucose levels, food intake, glucose production, gluconeogenesis, triglyceride levels, and low density lipoprotein (VLDL) levels in mammals are provided. Also provided are methods of increasing glucose production and food intake in mammals. Further provided are methods of treating a disorder selected from the group consisting of obesity, type 2 diabetes, type 1 diabetes, hyperglycemia, insulin resistance, glucose intolerance, leptin resistance, metabolic syndrome, heart failure, ischemia, coronary heart disease, familial lipoprotein lipase deficiency, hypopituitarism, hyperlipidemia, hypertriglyceridemia, hyperVLDLemia, atherosclerosis, hypercholesterolemia, hypertension, and any combination of the foregoing. The methods involve manipulations of amino acid presence or metabolism in the hypothalamus of the mammal. | 04-29-2010 |
20100035823 | LIGANDS OF SH3 DOMAINS - Provided are compounds that bind to SH3 domains. Also provided are combinatorial libraries for discovering such compounds. Methods of identifying a compound that binds to an SH3 domain are also provided. Methods of inhibiting an activity of a protein comprising an SH3 domain are additionally provided. Additionally provided are methods of inhibiting the activity of a protein comprising an SH3 domain and methods of treating a mammal having a deleterious condition that is mediated by a protein comprising an SH3 domain. The use of a compound that binds to the SH3 domain of a protein kinase in the manufacture of a medicament for the treatment of a deleterious condition in a mammal that is dependent on a protein kinase for induction or severity are also provided. | 02-11-2010 |
20090239952 | VITAMIN K FOR PREVENTION AND TREATMENT OF SKIN RASH SECONDARY TO ANTI-EGFR THERAPY - The invention provides methods and compositions tor treating and preventing a skin rash secondary to anti-epidermal growth factor receptor (BGKR) therapy, where the method comprises applying a vitamin K analog or a phosphatase inhibitor to the skin. | 09-24-2009 |
20090209652 | Vitamin K for Prevention and Treatment of Skin Rash Secondary to Anti-EGFR Therapy - The invention provides methods and compositions for treating and preventing a skin rash secondary to anti-epidermal growth factor receptor (EGFR) therapy, where the method comprises applying a vitamin K analog or a phosphatase inhibitor to the skin. | 08-20-2009 |
20090068152 | GENE TRANSFER FOR REGULATING SMOOTH MUSCLE TONE - The invention provides methods of regulating smooth muscle tone in a subject, comprising the introduction, into smooth muscle cells of the subject, of a DNA sequence encoding a potassium channel protein involved in the regulation of smooth muscle tone, and expression of the DNA sequence in a sufficient number of smooth muscle cells of the subject to regulate smooth muscle tone in the subject. The invention provides methods of gene transfer for treating erectile dysfunction, bladder dysfunction, and other smooth muscle disorders. | 03-12-2009 |
20080292622 | METHODS OF EVALUATING PATIENTS - Methods of treating patients and evaluating patients for disease stage and/or severity are disclosed. | 11-27-2008 |